



ASX Announcement

23rd January 2026

Atomo Q2 FY26 Quarterly Investor Webinar Presentation

SYDNEY Australia, 23rd January 2026 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) will release its Q2 FY26 Results on Wednesday, 28th January 2026.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly will be held on Wednesday, 28th January 2026 at 2:00 pm (AEDT).

To access the webinar please pre-register by clicking [this link](#).

We encourage you to utilise our Investor Hub for any enquiries. This platform offers an opportunity to submit questions prior to the webinar and share comments. To access Atomo's Investor Hub please scan the QR code or visit

<https://investors.atomodiagnosics.com/auth/signup>



~ ENDS ~

For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnosics.com
p. +61 401 922 279

Investor Queries
investorqueries@atomodiagnosics.com

This announcement was authorised by the Managing Director & CEO on behalf of the Board.

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnosics.com